Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

ducing remission, in patients whose disease was active despite ongoing treatment with methotrexate," said Edward Keystone, M.D., FRCPC, director of the Rebecca MacDonald Centre for Arthritis & Autoimmune Disease at Mount Sinai Hospital in Toronto, and lead study investigator. "Since some patients do not respond adequately to methotrexate alone, this combination therapy could prove to be a highly valuable treatment option based on these results."

Patients receiving golimumab also experienced improvement in physical function as assessed by the Health Assessment Questionnaire (HAQ). At 24 weeks, 68 percent of patients in the golimumab 50 mg dosing group and 72 percent of patients receiving golimumab 100 mg experienced clinically relevant improvement in physical function (improvement in HAQ score of at least 0.25 from baseline), compared with 39 percent of patients receiving placebo plus MTX (p<0.0001). HAQ assess the degree of difficulty a patient has in accomplishing tasks in eight functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and other activities of daily living).

At week 14, 74 percent and 76 percent of patients in the golimumab 50 mg and 100 mg plus MTX groups, respectively, were classified as DAS28 (using C-reactive protein [CRP]) responders, compared with 52 percent of patients receiving MTX alone (p<0.001). Importantly, 35 percent and 32 percent of patients in the respective golimumab groups achieved remission based on DAS28 (CRP), compared with 13 percent of patients receiving placebo plus MTX (p<0.001). These improvements were sustained through six months.

In another Phase 3 study, GOlimumab Before Employing methotrexate as the First-line Option in the treatment of Rheumatoid arthritis of Early onset (GO-BEFORE), MTX-naive patients treated with golimumab 50 mg or 100 mg in combination with MTX experienced improvement in signs and symptoms of arthritis as well as in disease activity. The study's primary
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Uroplasty, Inc. (NASDAQ: UPI ), a ... innovative proprietary products to treat voiding dysfunctions, today ... quarter ended June 30, 2014.  Global revenue ... grew 19% to $4.1 million, as compared to ... prior year.  Total revenue for the fiscal first ...
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014 /PRNewswire/ ... a leading provider of medication and supply management ... a conference call Thursday, July 31, to discuss ... , Omnicell Second Quarter 2014 earnings conference ... 1:30 p.m. PTWho:  , Randall Lipps, chairman, president ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2Alimera Sciences To Release Second Quarter 2014 Results 2
... WINDSOR, N.J. , July 7 ITelagen, a leading ... it was selected by Zweena, LLC of West Windsor, NJ ... ITelagen, which was selected for its expertise in EHR management, is ... solution. , , , ...
... DENVER , July 7 Invision Sally Jobe ... a new breast ultrasound technology for the early detection of cancer. Screening ... in women with radiologically dense breasts and other risk factors. , ... "Screening breast ultrasound is part ...
Cached Medicine Technology:Zweena Selects ITelagen to Host Personal Health Records Application 2Zweena Selects ITelagen to Host Personal Health Records Application 3Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 2Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 3Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver 4
(Date:7/24/2014)... MEMPHIS, Tenn. Researchers at Le Bonheur Children,s Hospital ... results of a clinical trial of a new drug ... illness of healthy adult volunteers intranasally infected with respiratory ... of lower respiratory tract infections in young children in ... comes from the labs of Infectious Disease Specialist John ...
(Date:7/24/2014)... 24, 2014 In signing the ... Obama cited the Atlanta BeltLine Workforce Partnership in ... across the country ( http://www.whitehouse.gov/ready-to-work ). The ... pillar of U.S. economic strategy and profiled successful ... recognition from President Obama highlights the power of ...
(Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... E. Taylor, M.D., director of The Miriam Hospital,s ... 2014 Rhode Island Medical Journal special ... c virus infection (hep c or HCV) is ... address other health challenges, and improve health care ... States, Taylor says, include lack of funding earmarked ...
Breaking Medicine News(10 mins):Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... Children who can read and have good phonetic skills - ... may still be poor spellers. In a paper published in ... Annett, at the School of Psychology of Leicester, UK, show ... be right-handed than other poor spellers. , The three-year study ...
... May 29 Alsius Corporation,(Nasdaq: ALUS ... (IVTM(TM)) therapies for critically ill patients, was ... L.P. to provide,intravascular temperature management products to ... the fifth contract we have been awarded ...
... to what is known about relationship between fitness and,diabetes, ... 2 diabetes in women is significantly increased as a ... Index (BMI), and a,combination of the two increases the ... at the 55th Annual Meeting of the American,College of ...
... a first for URAC, the,independent, non-profit accreditation organization ... has developed to help case management,practitioners assess patient ... instrument is a standardized assessment case managers,can voluntarily ... from any interested,parties, including purchasers, policy makers, consumers, ...
... that they have coordinated all the entertainment for Rhinestone ... Hotel Indigo, on,West End, from 7pm until midnight., ... a,place for you to connect with artists, friends and ... the world of country music quick, easy,and free!, ...
... firefighters study to be presented at ... American College of Sports Medicine, MISSOULA, ... Exercise Metabolism (Montana WPEM) will present a human,clinical study at ... that wildland firefighters who consumed a yeast based,(beta glucan) antioxidant ...
Cached Medicine News:Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 2Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 2Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 4Health News:URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument 2Health News:URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument 3Health News:DigitalRodeo.com Lines Up Entertainment for Rhinestone Cure 2Health News:Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study 2
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer ... day, 7 days per week. With rugged ... footprint. Powerwave breaks the barrier of traditional ... reliably. One instrument can easily read up ...
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
Medicine Products: